|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
In these cell lines, DIM-C significantly sensitized bladder cancer cell lines that were resistant to EGFR inhibition in a schedule-specific manner.
|
23409107 |
2013 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In epidermal growth factor receptor expressing bladder cancer co-expression of platelet-derived growth factor receptor-β has implications for tumor biology.
|
21168861 |
2011 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
The cytotoxicity of <sup>111</sup>In delivered by the EGFR-targeted MNT (<sup>111</sup>In-MNT) was greatly enhanced on EJ-, HT-1376-, and 5637-expressing EGFR bladder cancer cell lines compared with <sup>111</sup>In non-targeted control.
|
30510514 |
2018 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, it is reported that epidermal growth factor receptor ligands induced by the upregulation of vascular endothelial growth factor (VEGF)‑A and VEGF‑C via the VEGF receptor (R)2/nuclear factor‑κB signaling pathway in ECs, may trigger EGFR signaling in bladder cancer cells and promote bladder cancer progression.
|
30816487 |
2019 |
|
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These findings suggested that EGFR 3'UTR 774T>C polymorphism may contribute to susceptibility to bladder cancer.
|
23028094 |
2013 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The epidermal growth factor receptor (EGFR) family is reportedly overexpressed in bladder cancer, and tyrosine kinase inhibitors (TKIs) have been suggested as treatment.
|
25482142 |
2015 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phenformin alone or combined with gefitinib inhibits bladder cancer via AMPK and EGFR pathways.
|
30053908 |
2018 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
CXCR7 promotes BCa cell proliferation and motility plausibly through epidermal growth factor receptor receptor and Akt signaling.
|
22736438 |
2013 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression of the c-erbB-2 gene product and the epidermal growth factor receptor (EGF-R) was investigated in 54 cases of human bladder cancer immunohistologically and by Western blot analysis.
|
1988741 |
1991 |
|
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Haplotype analysis further revealed three haplotypes within VEGFC and two haplotypes in EGFR were significantly associated with increased bladder cancer risk compared to the most common haplotype.
|
23251617 |
2012 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, we aimed to investigate whether EGFR or HER2 may serve as a target for T cell-mediated immunotherapy against human bladder cancer.
|
29328392 |
2018 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, prognostic significance of HER1 and HER2 receptors in bladder cancer is controversial and the effect of the expression of different combinations of these receptors on patient survival is not well understood.
|
16685269 |
2006 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Previous in vitro studies demonstrated that leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1), a negative regulator of EGFR, is a novel agent for suppressing bladder cancer.
|
21567105 |
2011 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Using clinical specimens from different stages of bladder cancer, immunohistochemical staining was performed to determine if Id-1 expression was positively associated with tumour staging and EGFR expression.
|
16525633 |
2006 |
|
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest modified bladder cancer risk and survival associated with genetic variation in the EGFR pathway.
|
19372140 |
2009 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ErbB receptor tyrosine kinase family expression levels in urothelial bladder carcinoma.
|
23333248 |
2013 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We aimed to investigate the prognostic significance of EGFR expression in patients receiving cisplatin-based adjuvant chemotherapy following radical cystectomy for advanced BC.
|
30413194 |
2018 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, TRIP13 expression was positively correlated with EGFR expression in BCa specimens, and the high expression of both TRIP13 and EGFR predicted poor survival.
|
31337978 |
2019 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Exploring the roles of urinary HAI-1, EpCAM & EGFR in bladder cancer prognosis & risk stratification.
|
29861867 |
2018 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Epidermal growth factor receptor (EGFr)-targeted therapy may be used in subgroups of patients with urinary bladder cancer.
|
29508172 |
2018 |
|
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A total, 50 Moroccan patient specimens with bladder cancer and 48 healthy controls were analysed for EGFR mutations in the region delimiting exons 18-21 by PCR amplification and direct sequencing.
|
28719349 |
2017 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
No consensus as to the involvement of the epidermal growth factor receptor (EGF-R) in colorectal carcinomas has yet been attained, although they are assumed to play a role in the metastasis to lymph nodes and recurrence of breast carcinoma and bladder carcinoma invasion.
|
7781795 |
1995 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to establish an orthotopic human bladder carcinoma mouse model using the epidermal growth factor receptor (EGFR)-overexpressing bladder carcinoma cell line EJ28 and to compare therapeutic efficacy of intravesically instilled alpha-particle-emitting (213)Bi-anti-EGFR-monoclonal antibody (mAb) with mitomycin C.
|
19793735 |
2009 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Daily dosing of either non-steroidal anti-inflammatory drugs (NSAIDs) or EGFR inhibitors has been shown to prevent bladder cancer development in a N-butyl-(4-hydroxybutyl)nitrosamine (OH-BBN) induced rat model.
|
31818850 |
2020 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
The first evidence was provided that miR-133a and miR-133b may directly target the epidermal growth factor receptor in bladder cancer.
|
23206218 |
2013 |